Blumberg Institute staff participate in ICAR, Dr. Jinhong Chang Receives ISAR Award

The Blumberg Institute’s yellow fever research team recently took part in the International Conference on Antiviral Research (ICAR) in Prague, Czech Republic, where we were also proud event sponsors.


David Renner, PhD, and Julianna Deakyne, PhD, DABT, presented posters highlighting progress in our antiviral program, with David earning 1st Place in the Post-Doctoral Category. Yanming Du, PhD, also delivered an oral presentation on the development and lead optimization of a backup antiviral compound.


We’re also proud to share that Jinhong Chang, MD, PhD, received the Alice Ball Excellence Award, which recognizes outstanding scientific leadership, mentorship and commitment to inclusivity. As the recipient of this prestigious award, Dr. Chang gave a presentation at the conference, focusing on the presented on the yellow fever research program’s history and recent progress.


Congratulations to the entire team for representing the Institute on the international stage. More here.

Our founders among Bucks County's most prominent people

over the past 250 years

Congratulations to Tim and Joan Block, and Jan and Paul Witte on being recognized among Bucks County’s most notable figures in a recent Bucks County Courier Times feature highlighting influential people who have helped shape our community’s history and future. Read here.

Structures of hepatitis B virus subviral particles and identification of potential druggable pockets for the discovery of antiviral agents

The hallmark of chronic hepatitis B is the persistent presence of HBV surface antigen (HBsAg) in the circulation, which hampers the anti-HBV immune response. The sustained loss of serum HBsAg is the goal of a functional cure. In a recent publication, Blumberg faculty reviewed recent advances in the understanding of HBsAg molecular structure, and they predicted and report possible drug binding sites to aid development of a functional cure. More here.

The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a two-year R03 grant to support Dr. Liudi Tang’s research, in collaboration with Dr. Qiong Zhao

The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a two-year R03 grant, effective July 1, to support Dr. Liudi Tang’s research, in collaboration with Dr. Qiong Zhao, on hepatitis B virus (HBV) DNA integration.


HBV DNA integration into the chromosomes of infected hepatocytes is not required for viral replication but accumulates over time, contributes to cancer-promoting genetic changes, and enables continued production of viral antigens even when viral replication is suppressed. As a result, HBV integration represents a major obstacle to curing chronic hepatitis B and a key driver of hepatocellular carcinoma (HCC). To better understand how HBV integration can be prevented by antiviral therapies, Dr. Tang and Dr. Zhao will develop a novel quantitative assay to measure viral integration and evaluate the effects of antiviral drugs that target different stages of the HBV life cycle on HBV DNA integration.

Blumberg Institute announces a gift from

Distinguished Professor Richard Pestell

The Blumberg Institute has received a generous gift from Distinguished Professor Richard G. Pestell, AO., MD, PhD FACP, FRACP, MBA.

 

Dr. Pestell assigned the Blumberg Institute an equity position in his company StromaGenesis, which is valued at $88 million, two years ago and recently increased that equity position. He previously made another equity-based gift for another of his startup companies. Dr. Pestell previously assigned an equity position in his company ProstaGene shortly before its sale in 2018, which benefited research programs at the Blumberg Institute. These forward-thinking acts of philanthropy support the Institute’s mission and demonstrate Dr. Pestell’s passion for the Institute’s scientific research and drug development work. More here.

Biotech Insiders: Ep. 18

Episode 18 of Biotech Insiders is now live!


This episode features Jeff Marrazzo, co-founder of Spark Therapeutics, discussing his journey in human health and entrepreneurship.


You'll also learn about the PABC’s two new board members: Mark R. Schweiker, former Governor of Pennsylvania, and J. David Owens, biotech entrepreneur and executive. 


Listen here.

Upcoming Distinguished Speaker Seminars

Oct. 20 (11 a.m.) - Simon Fletcher, PhD, vice president, virology, Gilead Sciences


All seminars are hybrid unless otherwise noted.


To learn more about our Distinguished Speaker Seminar series click here.


The Blumberg Institute focuses on understanding the pathobiology of hepatitis B virus and related diseases, developing diagnostics for early detection of liver disease and the discovery of therapeutics, antivirals and immune modulators, aimed at curing hepatitis B and other severe viral diseases.

www.blumberginstitute.org

Linkedin